Good morning :)
$
₹
Seres Therapeutics Inc

Seres Therapeutics Inc

MCRB

NASDAQ
Asset Logo

Seres Therapeutics Inc

MCRB

NASDAQ
$2.013.54% (-0.07)
$
₹
$2.013.54% (-0.07)
High
—
—
Low
—
—
Returns
—
—
Loading...
1D
1W
1M
3M
6M
1Y
3Y
5Y
Max

Healthcare

Biotechnology

Micro Cap

With a market cap of $21.0M the stock is ranked 5420

Key Metrics

Key Metrics

PE TTM
PE TTM

Close price divided by the earnings per share for the trailing twelve months

—
PB
PB

Close price divided by the book value per share at the end of the most recent quarter

1.17
EPS TTM
EPS TTM

Net profit earned per share over the trailing twelve months (sum of the last 4 quarters)

$-2.42
PEG Ratio
PEG Ratio

Price-to-Earnings (P/E) ratio divided by the forecasted annual earnings per share (EPS) growth rate over the next five years

-0.11
Profit Margin
Profit Margin

Net profit divided by the total revenue for the most recent financial year

0%
Dividend Yield
Dividend Yield

Annual dividend per share for the trailing twelve months divided by the close price

—

Analyst Ratings & Forecast

Analyst Ratings & Forecast

Detailed Forecast Detailed Forecast 

Based on 2 analysts reports

Buy
2 analysts
Hold
0 analyst
Sell
0 analyst

Price Upside

+713.4%

Earnings Growth

+34.05%

Rev. Growth

+1648.67%

See Detailed Forecast

Company Profile

Company Profile

Seres Therapeutics, Inc., a clinical-stage company, focuses on developing biotherapeutics for serious diseases. The company develops SER-155, an investigational oral live biotherapeutic to decolonize GI pathogens, enhance GI epithelial barrier integrity, and regulate immune response to prevent bacterial bloodstream infections, as well as other pathogen-associated negative clinical outcomes in patients undergoing allogeneic hematopoietic stem cell transplantation. It also develops SER-603, a LBP candidate optimized to treat disruptions in the GI microbiome and to improve GI mucosal barrier integrity through the inhibition of inflammatory bacteria and associated metabolites; and SER-147, a live biotherapeutic composition to prevent bacterial bloodstream and spontaneous bacterial peritonitis infections in patients with metabolic disease, including chronic liver disease. The company was formerly known as Seres Health, Inc. and changed its name to Seres Therapeutics, Inc. in May 2015. Seres Therapeutics, Inc. was incorporated in 2010 and is headquartered in Cambridge, Massachusetts.
Seres Therapeutics, Inc., a clinical-stage company, focuses on developing biotherapeutics for serious diseases. The company develops SER-155, an investigational oral live biotherapeutic to decolonize GI pathogens, enhance GI epithelial barrier integrity, and regulate immune response to prevent bacterial bloodstream infections, as well as other pathogen-associated negative clinical outcomes in patients undergoing allogeneic hematopoietic stem cell transplantation. It also develops SER-603, a LBP candidate optimized to treat disruptions in the GI microbiome and to improve GI mucosal barrier integrity through the inhibition of inflammatory bacteria and associated metabolites; and SER-147, a live biotherapeutic composition to prevent bacterial bloodstream and spontaneous bacterial peritonitis infections in patients with metabolic disease, including chronic liver disease. The company was formerly known as Seres Health, Inc. and changed its name to Seres Therapeutics, Inc. in May 2015. Seres Therapeutics, Inc. was incorporated in 2010 and is headquartered in Cambridge, Massachusetts.

Peers

Compare with peers Compare with peers 

Peers

Compare with peers Compare with peers 
AbbVie Inc
ABBV
AbbVie Inc
P/E Ratio
80.68
80.68
1Y Return
24.94%
24.94%
Buy Reco %
80.00
80.00
Amgen Inc
AMGN
Amgen Inc
P/E Ratio
27.28
27.28
1Y Return
51.04%
51.04%
Buy Reco %
35.29
35.29
Gilead Sciences Inc
GILD
Gilead Sciences Inc
P/E Ratio
—
—
1Y Return
29.23%
29.23%
Buy Reco %
78.57
78.57
Vertex Pharmaceuticals Inc
VRTX
Vertex Pharmaceuticals Inc
P/E Ratio
29.90
29.90
1Y Return
23.96%
23.96%
Buy Reco %
81.25
81.25
Moderna Inc
MRNA
Moderna Inc
P/E Ratio
—
—
1Y Return
662.28%
662.28%
Buy Reco %
21.73
21.73
Compare with Peers

Forecast

Forecast

Price

Revenue

Earnings

Price Forecast

Price Forecast

Higher price growth forecast versus trailing 3-year CAGR
Compares analyst forecast growth with historical annualized growth.

The 12-month consensus target implies 713.40% growth, versus a trailing 3-year CAGR of -59.12%.

2026
Current$2.09Baseline
Analyst Target - 1 year
Target$17+713.4%

All values in $

202220232024202520262027$32.21$62.54$92.87Target+713.4%
2026
Current$2.09Baseline
Analyst Target - 1 year
Target$17+713.4%

All values in $

Revenue Forecast

Revenue Forecast

2025
Current$0.78Baseline
Forecast for Dec 2026
High$26.09+3207.22%
Average$13.79+1648.67%
Low$1.5+90.11%

All values in $ Million

202120222023202420252026144.927.12126.3200.78Low+90.11%Average+1648.67%High+3207.22%
2025
Current$0.78Baseline
Forecast for Dec 2026
High$26.09+3207.22%
Average$13.79+1648.67%
Low$1.5+90.11%

All values in $ Million

Earnings Per Share Forecast

Earnings Per Share Forecast

2025
Current$-5.33Baseline
Forecast for Dec 2026
High$-2.67+49.91%
Average$-3.52+34.05%
Low$-4.36+18.2%

All values in $

202120222023202420252026-4.52-36.54-11.92-16.51-5.33Low+18.2%Average+34.05%High+49.91%
2025
Current$-5.33Baseline
Forecast for Dec 2026
High$-2.67+49.91%
Average$-3.52+34.05%
Low$-4.36+18.2%

All values in $

Financials

Financials

Income

Balance Sheet

Cash Flow

0.3
8.2
0.4
-15.3
0.3
-19.9
0.7
4.5
Q3 2025
Q4 2025
Q1 2026
Q2 2026
Revenue
Net Income
Financial YearQ1 2024Q2 2024Q3 2024Q4 2024Q1 2025Q2 2025Q3 2025Q4 2025Q1 2026Q2 2026
Total Revenue0005.95000.350.430.350.73
Net Income-40.13-32.8788.77-15.6332.68-19.858.20-15.33-19.914.58
Net Profit Margin----262.45%--2337.32%-3501.14%-5562.29%622.41%
See CostsAll values in $ Million

Peers

Peers & Comparison

Peers & Comparison

Comparing 2 stocks from
HealthcareBiotechnology

Valuation

Returns

Forecast

ScreenerCompare valuation on Screener
StockPE TTMPE TTMPBPBPEG RatioPEG Ratio
Seres Therapeutics Inc -1.17-0.11
AbbVie Inc80.6850.450.53
Amgen Inc27.2817.562.28
ScreenerCompare valuation on Screener

Price Comparison

Price Comparison

Compare MCRB with any stock or ETF
Compare MCRB with any stock or ETF
Comparing from
MCRB
ABBV
AMGN
Loading...

Frequently asked questions

  1. Seres Therapeutics Inc (MCRB) share price today is $2.01 as of October 27, 2026 at 1:29 AM IST. The stock touched a day high of $2.21 and a day low of $1.99.

  2. Seres Therapeutics Inc stock trades on NASDAQ under the ticker symbol MCRB.

  3. Seres Therapeutics Inc's market capitalization is $20.99M as of October 27, 2026 at 1:29 AM IST.

  4. Seres Therapeutics Inc's price-to-earnings (P/E) ratio is N/A as of October 26, 2026.

  5. Seres Therapeutics Inc's price-to-book (P/B) ratio is 1.17 as of October 26, 2026.

  6. Yes, You can buy Seres Therapeutics Inc shares from India through Tickertape, via our partnership with ViewTrade IFSC under the IFSCA Global Access framework, subject to RBI’s Liberalised Remittance Scheme (LRS) limits.

  7. Indian investors can buy Seres Therapeutics Inc shares in three steps: 1. Search Seres Therapeutics Inc on the Tickertape app and tap Invest. 2. Complete your one-time digital KYC. 3. Fund your account and buy from as low as $1 via fractional shares.

  8. Since Seres Therapeutics Inc trades in USD, an Indian investor's INR returns depend on both the stock's price movement and the USD-INR exchange rate. If the rupee depreciates against the dollar, INR returns are boosted beyond the stock's USD return; if the rupee appreciates, INR returns are reduced.

  9. Indian investors can start investing in Seres Therapeutics Inc (MCRB) shares from as little as $1 through fractional ownership on Tickertape - for example, $10 buys approximately 4.9603 shares at the current price of $2.01.

Loading...